| Targeting hypoxia in cancer therapy WR Wilson, MP Hay Nature Reviews Cancer 11 (6), 393-410, 2011 | 3433 | 2011 |
| Exploiting tumour hypoxia in cancer treatment JM Brown, WR Wilson Nature Reviews Cancer 4 (6), 437-447, 2004 | 3305 | 2004 |
| Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review M Kanamala, WR Wilson, M Yang, BD Palmer, Z Wu Biomaterials 85, 152-167, 2016 | 960 | 2016 |
| Therapeutic targeting of the hypoxic tumour microenvironment DC Singleton, A Macann, WR Wilson Nature reviews Clinical oncology 18 (12), 751-772, 2021 | 311 | 2021 |
| Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104 AV Patterson, DM Ferry, SJ Edmunds, Y Gu, RS Singleton, K Patel, ... Clinical Cancer Research 13 (13), 3922-3932, 2007 | 271 | 2007 |
| A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells GJ Finlay, BC Baguley, WR Wilson Analytical Biochemistry 139 (2), 272-277, 1984 | 262 | 1984 |
| Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt (III) complexes … DC Ware, BD Palmer, WR Wilson, WA Denny Journal of medicinal chemistry 36 (13), 1839-1846, 1993 | 248 | 1993 |
| DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogs of pibenzimol (Hoechst 33258) GL Gravatt, BC Baguley, WR Wilson, WA Denny Journal of medicinal chemistry 37 (25), 4338-4345, 1994 | 246 | 1994 |
| Hypoxia-activated prodrugs: paths forward in the era of personalised medicine FW Hunter, BG Wouters, WR Wilson British journal of cancer 114 (10), 1071-1077, 2016 | 230 | 2016 |
| The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3 CP Guise, MR Abbattista, RS Singleton, SD Holford, J Connolly, ... Cancer research 70 (4), 1573-1584, 2010 | 198 | 2010 |
| Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs KO Hicks, FB Pruijn, TW Secomb, MP Hay, R Hsu, JM Brown, WA Denny, ... Journal of the National Cancer Institute 98 (16), 1118-1128, 2006 | 182 | 2006 |
| Blood flow failure as a major determinant in the antitumor action of flavone acetic acid LJ Zwi, BC Baguley, JB Gavin, WR Wilson JNCI: Journal of the National Cancer Institute 81 (13), 1005-1013, 1989 | 179 | 1989 |
| Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells WA Denny, WR Wilson Journal of medicinal chemistry 29 (6), 879-887, 1986 | 167 | 1986 |
| Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N, N-bis (2-chloroethyl) anilines BD Palmer, WR Wilson, SM Pullen, WA Denny Journal of medicinal chemistry 33 (1), 112-121, 1990 | 159 | 1990 |
| Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores M Tercel, SM Stribbling, H Sheppard, BG Siim, K Wu, SM Pullen, ... Journal of medicinal chemistry 46 (11), 2132-2151, 2003 | 157 | 2003 |
| Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104 J Benito, Y Shi, B Szymanska, H Carol, I Boehm, H Lu, S Konoplev, ... PloS one 6 (8), e23108, 2011 | 148 | 2011 |
| Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors KO Hicks, BG Siim, JK Jaiswal, FB Pruijn, AM Fraser, R Patel, A Hogg, ... Clinical Cancer Research 16 (20), 4946-4957, 2010 | 143 | 2010 |
| Recent developments in the design of bioreductive drugs WA Denny, WR Wilson, MP Hay The British journal of cancer. Supplement 27, S32, 1996 | 142 | 1996 |
| Structure− activity relationships of 1, 2, 4-benzotriazine 1, 4-dioxides as hypoxia-selective analogues of tirapazamine MP Hay, SA Gamage, MS Kovacs, FB Pruijn, RF Anderson, AV Patterson, ... Journal of medicinal chemistry 46 (1), 169-182, 2003 | 140 | 2003 |
| Interaction of the antitumor drug 4'-(9-acridinylamino) methanesulfon-m-anisidide and related acridines with nucleic acids WR WILSON, BC BAGULEY, LPG WAKELIN, MJ WARING Molecular Pharmacology 20 (2), 404-414, 1981 | 138 | 1981 |
